Functional Concept
Draig Therapeutics Raises $140M Series A to Advance Neuropsychiatric Drug Pipeline
Draig Therapeutics; $140M Series A; neuropsychiatric drugs; DT-101; depression treatment; AMPA receptor modulator; GABA modulators; biotech funding; Cardiff University; SV Health Investors
FDA Launches New Priority Review Voucher Program Aligned with National Priorities
FDA; priority review voucher; CNPV; biopharma; drug approval; national priorities; accelerated review; unmet public health needs
IPG Health Leads at Cannes Lions 2025 as Real Chemistry and Ogilvy Health Earn Major Awards
Cannes Lions 2025; IPG Health; Real Chemistry; Ogilvy Health; healthcare marketing; agency awards; Health & Wellness Lions; Grand Prix; AREA 23; Vaseline Verified
Lark Health Launches LarkVantage: AI-Powered Platform to Manage GLP-1 Costs
Lark Health; LarkVantage; GLP-1 cost management; AI healthcare; prior authorization; utilization management; PBM; health plans; weight management; Matthew Gibbs
Lilly Makes All Zepbound Doses Available via Direct Pay Program
Zepbound; Eli Lilly; direct pay; LillyDirect; tirzepatide; obesity medication; dose availability; pharmacy platform
FDA Delays Decision on KalVista’s HAE Drug Sebetralstat, Citing Heavy Workload
KalVista Pharmaceuticals; sebetralstat; FDA delay; hereditary angioedema; resource constraints; PDUFA date; drug approval; oral on-demand treatment
Lilly Posts Encouraging Early-Stage Weight Loss Data on Amylin Candidate
Eli Lilly; eloralintide; amylin candidate; weight loss; early-stage trial; obesity drug; clinical data; side effects
Novo Nordisk Strikes Major Deal with Deep Apple Therapeutics for Oral Cardiometabolic Medicines
Novo Nordisk; Deep Apple Therapeutics; cardiometabolic diseases; oral medicines; obesity; small molecule therapeutics; GPCR target; R&D collaboration; biotech partnership
FDA Reinstates Generic Drug Policy Group After April Firings
FDA; generic drugs; policy office; Division of Policy Development; reinstatement; layoffs; drug prices; administrative leave
FDA Places Clinical Hold on Five Gilead HIV Studies Due to Safety Concerns
FDA; Gilead Sciences; HIV; clinical hold; GS-1720; GS-4182; clinical trials; safety signal; CD4+ T-cell; lymphocyte count; Biktarvy; lenacapavir